Kiora Pharmaceuticals (KPRX) Non-Current Debt (2020 - 2021)

Kiora Pharmaceuticals' (KPRX) quarterly Non-Current Debt came in at $278190.0 in Q1 2021, little changed on a QoQ basis from $278190.0 in Q4 2020.

Kiora Pharmaceuticals (KPRX) Non-Current Debt (2020 - 2021) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has 2 years of Non-Current Debt data on file, last reported at $278190.0 in Q1 2021.

Quarterly Non-Current Debt changed N/A year-over-year to $278190.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $278190.0 (changed N/A YoY) and the FY2020 annual result came in at $278190.0, changed N/A from the prior year.
Non-Current Debt held at $278190.0 in Q1 2021, from $278190.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $278190.0 in Q2 2020 to a low of $278190.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Kiora Pharmaceuticals	15.64 Mn	15.64 Mn	-	-

Download Data